PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Phenotype | C0024523|malabsorption |
| Sentences | 7 |
| PubMedID- 25782658 | Objectives: pancreatic enzyme replacement therapy (pert) is the proven therapy to substantially reduce fat malabsorption in patients with cystic fibrosis (cf). |
| PubMedID- 26410283 | Pulmonary exacerbations and malabsorption in children with cystic fibrosis (cf) can lead to faltering growth and poor weight gain. |
| PubMedID- 22175008 | [224, 225] hypothesized that gln should be readily absorbed in cystic fibrosis children with malabsorption secondary to exocrine pancreatic insufficiency and maybe of potential benefit. |
| PubMedID- 21197074 | Pancreatic enzyme replacement therapy is the standard of care for treatment of malabsorption in patients with cystic fibrosis (cf) and exocrine pancreatic insufficiency (pi). |
| PubMedID- 20179641 | Fat malabsorption in cystic fibrosis: comparison of quantitative fat assay and a novel assay using fecal lauric/behenic acid. |
| PubMedID- 24743047 | Background: pancreatic insufficiency is common in patients with cystic fibrosis (cf) and leads to malabsorption of fat-soluble vitamins. |
| PubMedID- 21459688 | Persistent fat malabsorption in cystic fibrosis; lessons from patients and mice. |
Page: 1